【汇宇制药：注射用HY0001a药物临床试验申请获受理】金十数据4月11日讯，汇宇制药晚间公告，全资子公司四川汇宇海玥医药科技有限公司收到国家药监局核准签发的《受理通知书》，注射用HY0001a用于治疗晚期实体瘤的临床试验申请获得受理。截至目前，国内外尚无同靶点产品获批上市。本品为全球首个披露针对该靶点推向临床的药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.